Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Pediatric MDD
NCT02709746Phase 3Completed
- Sponsor
- Lundbeck
- Start
- May 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started May 2016; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02709746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709746.